Commentary

Compassionate use and hospital exemption for regenerative medicine: Something wrong to apply the program for patients in a real world

Kazuo Yano 1, Masayuki Yamato*

Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

ARTICLE INFO

Article history:
Received 7 February 2018
Accepted 14 March 2018

Keywords:
Compassionate use
Hospital exemption
Expanded access
Regenerative medicine products
Advanced therapy medicinal products (ATMPs)
Human cells
Tissues and cellular and tissue-based products (HCT/Ps)
Stem cell products

ABSTRACT

“Compassionate use” or “Hospital exemption” provides an important pathway for patients with life-threatening conditions to gain access to unproved human cells and tissue products. In a real world, any practitioners may not comply with relevant system. Such regulation should establish an international registry of clinical practices of stem cell therapy as well as provide education for patients to prevent deception by the spread of misinformation by testimonials on websites.

We read the World Report titled “The dangers of unregulated stem-cell marketing” by Dara Mohammadi [1] with great interest. The article mentions that the United Kingdom (UK) and Europe have the Medicines and Healthcare Products Regulatory Agency (MHRA) and European Medicines Agency (EMA), respectively, that regulate cell therapy treatments for patients in need [1].

However, in the European Union (EU) the “Compassionate use programs” are only for patients that have life-threatening or severely debilitating diseases which cannot be treated satisfactorily with any currently authorized medicine [2]. The medicine must be undergoing clinical trials or have entered the marketing authorization application process [2]. Furthermore, the advanced therapy medicinal product (ATMP) compromising a somatic cell therapy medicinal product, a tissue engineered product, and a gene therapy medicinal product in the EU also has the centralized marketing authorization application process among the EU members states [3]. As exception of the centralized marketing authorization application process under so-called ATMP regulation, Regulation (EC) No 1394/2007, the “Hospital exemption” under the article 28 of ATMP regulation allows to member states that enables to permit the use of ATMPs in their territories without the requirement for marketing authorization [4]. The article applies only to custom-made ATMPs used in a hospital setting for a specific patient in situations of high unmet medical need and where no authorized products are available [4]. Such products are produced under the responsibility of a physician and are only to be used within the member state where it is produced [4]. In addition, a competent authority must authorize “Hospital exemption” for ATMPs and they must comply with the same national requirements concerning quality, traceability and pharmacovigilance that apply to authorized medicinal products [4].

Then, in the United States (US) the “Compassionate exemption” or “Special exception” is for patients who do not meet the eligibility criteria for a clinical trial of an investigational drug available for cancer treatment according to access investigational drugs of National Cancer Institute (NCI) at the National Institutes of Health (NIH) [5]. Sometimes called “Compassionate use”, mostly “Expand access” is the use outside of clinical trial of investigational drugs, biologics, and medical devices [6]. The “Compassionate use” provides an important pathway for patients with life-threatening conditions to gain access to unproved investigational drugs, medical devices, and biologics including human cells and tissue.
products [7]. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a patient may seek “individual patient expanded access” to investigational products for the diagnosis, monitoring, or treatment of a serious disease or condition [6]. Physician may submit a protocol intended to provide widespread access to an investigational product for multiple patients under a treatment Investigational New Drug Application (IND) or treatment Investigational Device Exemption (IDE) [6,7].

In Japan, as of 2015 there was such “Compassionate use” or “Expanded access” as the US but unapproved products were used under a physician’s discretion in compliant with Japan Medical Practitioner’s Act or Advanced Medical Care [7]. As this moment, however, the “Compassionate use” or “Expanded access” applies for investigational drugs, medical devices, or regenerative medicine products when the patients who could not meet the eligible criteria need during a clinical trial or after completing the clinical trial prior to approval [8].

Small and Medium Size Enterprise has the option not to participate in such programs. Participation in such programs can be prohibitively expensive for small biotech companies and potentially pose challenges in getting experimental products approved since this access occurs outside of the scrutiny of a clinical trial but can still be subject to scrutiny by regulatory agencies.

In Japan, a new law, “The Act on the Safety of Regenerative Medicine”, came into effect in 2014 to regulate medical professionals’ practices and clinical studies related to regenerative medicine [9]. Similar to the ethical and scientific board application approvals usually needed in the UK and Europe for patients [10] that might qualify for “Compassionate exception” cell therapy treatments, all protocols under this new Act in Japan need pre-approval by specific ethical and scientific committees to demonstrate that appropriate accommodations are made to mitigate the presumed risks [9]. The regulation of this new legislation appears to have teeth in 2017, 11 clinics were inspected by the Japanese Ministry of Health, Labor and Welfare (MHLW) and six people were arrested for violating this new law by injecting patients with umbilical cord blood for aesthetic and anti-aging purposes without appropriate approval [11]. Thus, although, as the article acknowledges, establishing an international standard to ensure and enforce safe and effective regulation of cell therapies, the recent statement released by the Food and Drug Administration (FDA) on future regulatory changes to come [12] and the crackdowns on rogue clinics [12] and practices around the world [13–15] that have been found to be peddling unsafe cell therapies indicate that there is an international interest in regulating cell therapies. Such regulation should establish an international registry of clinical practices of stem cell therapy as well as provide education for patients to prevent deception by the spread of misinformation by testimonials on websites. Such provisions would protect the integrity of stem cell therapy research and prevent the unscrupulous few from tarnishing the promise of the nascent field.

**Contributions**

Dr. Yano drafted the manuscript with references; Dr. Yamato planned and organized this study as a corresponding author.

**Competing interests**

Dr. Yano is also an employee of Medtronic Japan Co., Ltd., and Dr. Yamato is a shareholder of CellSeed Inc.

**Acknowledgements**

Nothing should be declared.

**References**

[1] Mohammadi D. The dangers of unregulated stem-cell marketing. Lancet (London, England) 2017;390:1823–4. https://doi.org/10.1016/s0140-6736(17)32358-9.

[2] The European Parliament and of the Council of 31 March 2004. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. 2004. Official Journal, L 136, 30.4.2004, 1-70.

[3] The European Parliament and of the Council of 13 November 2007. Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Reg (EC) No 726/2004. 2007. Official Journal L324, 10 December, 2007, 123-37.

[4] The European Medicines Agency. Advanced therapy medicines: exploring solutions to foster development and expand patient access in Europe - Outcome of a multi-stakeholder meeting with experts and regulators held at EMA on Friday 27 May 2016. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/06/WC500208080.pdf.

[5] The National Cancer Institute at the National Institutes of Health. Access to Investigational Drugs. 2017. https://www.cancer.gov/about-cancer/treatment/drugs/investigational-drug-access-fact-sheet#q3.

[6] The Food and Drug Administration. Expanded Access (Compassionate Use), 2017. https://www.fda.gov/newsevents/publichealthfocus/expandedaccesscompassionateuse/default.htm.

[7] Tuyuki K, Yano K, Watanabe N, Aruga A, Yamato M. Compassionate use of drugs and medical devices in the United States, the European Union and Japan. Regen Ther 2016:4:18–26. https://doi.org/10.1016/j.reth.2015.11.002.

[8] Fujisawa Y. Evolution of frameworks for expediting access to new drugs in Japan. Nat Rev Drug Discov 2016;15:292–4. https://doi.org/10.1038/nrd.2016.68.

[9] Okano H. Stem cell research and regenerative medicine in 2014: first year of regenerative medicine in Japan. Stem Cell Dev 2014;23:2127–8. https://doi.org/10.1089/scd.2014.0200.

[10] Borysowski J, Ehn HJ, Gorski A. Ethics review in compassionate use. BMC Med 2017;15:136. https://doi.org/10.1186/s12916-017-0910-9.

[11] Ministry of Health Labour and Welfare. An emergency order issued based on the Act to Ensure the Safety of Regenerative Medicine, etc. 2017. http://www.mhlw.go.jp/english/new-info/index.html, http://www.mhlw.go.jp/stf/houdou/0000169320.html, http://www.mhlw.go.jp/file/04-Houdouhappou/10800-0001693319.pdf (in Japanese).

[12] The Food and Drug Administration Commissioner Scott Gottlieb, M. D. FDA Statement: Statement from FDA Commissioner Scott Gottlieb, M.D. on the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine., 2017 <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573443.htm>.

[13] Mendick R, Hall A. Europe’s largest stem cell clinic shut down after death of baby. 2011. http://www.telegraph.co.uk/news/worldnews/europe/germany/8500233/Europes-largest-stem-cell-clinic-shut-down-after-death-of-baby.html.

[14] Margottini L. Final chapter in Italian stem cell controversy?. 2014. http://www.sciencemag.org/news/2014/10/final-chapter-italian-stem-cell-controversy.

[15] Rosemann A, Sleeboom-Faulkner M. New regulation for clinical stem cell research in China: expected impact and challenges for implementation. Regen Med 2016;11:5–9. https://doi.org/10.22121/rme.15.80.